ArticleJournal of immunology (Baltimore, Md. : 1950)2026
Preconditioning determines engraftment and therapeutic efficacy of anti-CD19 CAR-T cells in murine lupus.
Article in Journal of immunology (Baltimore, Md. : 1950), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Anti-CD19 chimeric antigen receptor (CAR) T cells have emerged as a promising therapeutic strategy for autoimmune diseases, including systemic lupus erythematosus. An unresolved question is how immunosuppressive preconditioning regimens influence CAR-T cell engraftment and therapeutic efficacy. In murine models, whole-body irradiation is required for optimal CAR-T cell engraftment. However, irradiation alone can ameliorate lupus disease, confounding attribution of CAR-T-specific effects. To delineate the contribution of CAR-T cells beyond irradiation, we investigated how conditioning intensity shapes immunologic and physiological outcomes in lupus-prone New Zealand Black/New Zealand White (NZB/W) F1 mice. We generated murine anti-CD19 CAR-T cells incorporating a CD28 costimulatory domain and compared their efficacy following low-, intermediate- and high-dose irradiation. High-dose irradiation induced disease improvement that limited mechanistic discrimination between irradiation- and CAR-T-mediated effects, whereas low-dose irradiation failed to support durable CAR-T cell engraftment. In contrast, an intermediate-dose irradiation regimen in 22-week-old mice achieved consistent CAR-T cell engraftment in lymphoid organs while minimizing irradiation-driven disease modulation. Under these conditions, CAR-T cell treatment induced significant depletion of B cells in blood and spleen, including naïve B cells, marginal zone B cells, and plasma cells, accompanied by reduced anti-double-stranded DNA antibody levels and prevention of renal disease progression. Collectively, these findings demonstrate that intermediate-intensity conditioning enables mechanistic separation of CAR-T-mediated immune remodeling from irradiation effects in murine lupus and provide a preclinical framework that aligns with the pressing need for reduced-intensity lymphodepletion strategies in human CAR-T therapy for autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.